Summary of characteristics at baseline by insulin use at baseline
| No insulin | Insulin | |
| Subjects n | 488 | 708 |
| Female | 237 (48.6) | 364 (51.4) |
| Age years | 25.3±12.0 | 21.9±9.0 |
| Genotype# | ||
| High risk | 395 (80.9) | 618 (87.3) |
| Low risk | 33 (6.8) | 14 (2.0) |
| Not assigned | 60 (12.3) | 76 (10.7) |
| FEV1 % | 64.6±22.0 | 64.2±21.4 |
| Change in previous 12 months¶ | −1.0±10.6 | −2.8±10.5 |
| BMI z-score | −0.11±1.29 | −0.28±1.20 |
| Change in previous 12 months¶ | −0.04±0.50 | 0.00±0.60 |
| Pseudomonas aeruginosa infection | 295 (60.5) | 468 (66.1) |
| Burkholderia cenocepacia complex infection | 28 (5.7) | 28 (4.0) |
| Staphylococcus aureus infection | 195 (40.0) | 302 (42.7) |
| Pancreatic enzyme supplements use | 418 (85.7) | 637 (89.9) |
| Maximum years of post-baseline follow-up | ||
| 1 | 55 (11.3) | 79 (11.2) |
| 2 | 58 (11.9) | 106 (15.0) |
| 3 | 78 (16.0) | 118 (16.7) |
| 4 | 75 (15.4) | 81 (11.4) |
| 5 | 222 (45.5) | 324 (45.8) |
Continuous variables are summarised using mean±sd and categorical variables are summarised using n (%). FEV1 %: % predicted forced expiratory volume in 1 s; BMI: body mass index. #: genotype risk as described by Mckone et al. [34]. ¶: changes in FEV1 % and BMI are the changes from previous visit (i.e. difference between measures 2 years prior to cystic fibrosis-related diabetes diagnosis and 1 year prior to CFRD diagnosis).